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Background: Angiogenesis is involved in many cardiovascular and cancerous diseases, including 
atherosclerosis and is controlled by a fine balance between angiogenic and angiostatic mediators. 
Endostatin is one of the main angiostatic mediators, and inhibits angiogenesis and prevents 
progression of atherosclerosis. The available literature shows a broad range of concentrations in 
relatively small samples of healthy controls and is calculated by using different techniques. This 
study was aimed to determine the basal endostatin concentration in plasma of healthy volunteers, 
to fully understand its physiological role. Methods: Fifty healthy adult volunteers were recruited 
to the study. Participants were advised not to participate in any physical activity on the day before 
the blood sampling. The volunteers’ physical activity, height, weight, heart rate and blood pressure 
were recorded. The samples were analysed for plasma endostatin concentration, using ELISA. The 
participants were divided by gender and ethnic groups to calculate any difference. Results: 
Endostatin and other variables were normally distributed. Most of the participants had a moderate 
level of physical activity with no gender related difference (p=0.370). The mean value for plasma 
endostatin in all samples was 105±12 ng/ml with range of 81–132 ng/ml. For males, it was 107±13 
ng/ml, while for females; 102±12 ng/ml. There were no significant gender or ethnicity related 
differences in endostatin concentration. Moreover, endostatin was not significantly related with 
any anthropometric and physical variable. Conclusion: This study gives endostatin levels in 
normal healthy people and show no gender and ethnicity related differences in endostatin levels. 
Endostatin was not related with any anthropometric and physical variable. 
Keywords: Endostatin; Vascular endothelial growth factor; Angiogenesis; Atherosclerosis; Ethnic groups 
J Ayub Med Coll Abbottabad 2017;29(2):200–6  
INTRODUCTION 
Angiogenesis contributes to the progression and 
maturity of many cardiovascular and cancerous 
diseases including atherosclerosis.1 There is a fine 
balance between the angiogenic and angiostatic 
mediators in the overall process of angiogenesis and 
shift in favour of any particular phenotype determines 
the outcome of angiogenesis.2 The angiogenic 
mediators like VEGF and FGF favour angiogenesis, 
while endogenous angiostatic mediators, including 
angiostatin and endostatin tend to stop the angiogenic 
process.3 Endostatin, discovered by O’Reilly et al in 
1997, has come to the front as one of the main 
angiostatic mediators.4 Endostatin plays an essential 
role in control of the angiogenesis. By inhibiting 
angiogenesis, endostatin prevents progression of 
atherosclerosis5, primary growth of tumours and 
metastasis.4 
Endostatin is a small globular protein 
attached through a hinge to the C terminus of collagen 
XV and XVIII in the basement membrane of 
endothelial cells.6 It is also found in many other body 
tissues including heart, skeletal muscles, liver, 
placenta, ovaries, prostate and kidneys.7 The available 
literature contains several studies reporting the 
concentration of endostatin in the plasma (Table-1). 
Table-1 show that the sample populations are often 
small and drawn from patients with a range of 
pathologies. Moreover, shows a broad range of 
concentrations in relatively small samples of healthy 
controls. In addition, a variety of analytical techniques 
have been used. Thus the current literature does not 
provide the average plasma concentration in healthy 
human population.8 Some studies have reported the 
plasma endostatin concentration as low as 1.0 ng/ml 
while others have reported this level to be in the range 
of 300 ng/ml (Table-1). These huge differences in 
means and ranges are not completely clear. It is clear 
from the table, that for the determination of endostatin 
concentration in plasma, different methods like mass 
spectrometry, radioimmunoassay, western blots and 
ELISA have been used frequently.  
The difference in the reference range could 
possibly be due to use of different techniques. However, 
even the same techniques used in different studies have 
reported significant differences in the basal plasma 
endostatin concentrations.9,10 This study was aimed to 
determine the basal endostatin concentration in plasma 
of healthy volunteers. In addition, difference in basal 
endostatin concentration with gender, age, height, 
J Ayub Med Coll Abbottabad 2017;29(2) 
http://www.jamc.ayubmed.edu.pk 201
weight, and physical activity behaviour of the 
individuals will also be evaluated.  
MATERIAL AND METHODS 
The experimental protocol was approved by the 
University of Glasgow, College of Medical, 
Veterinary and Life Sciences Ethics committee. 
All recruitments and experimental procedures were 
carried out in the different labs of school of Life 
Sciences. Volunteers were enrolled to the study, 
after initial screening by asking questions about 
the inclusion and exclusion criteria. The 
participants belonged to 3 main geographical 
regions, Europe, Asia and Middle East. 
Participants were advised not to 
participate in any physical activity on the day 
before the blood sample. In total, 50 healthy adult 
volunteers were recruited to the study. The 
characteristics of the volunteers are summarised in 
table-2, which subdivides the data by gender to 
allow comparison. Another table-3 shows these 
data by geographical origin of the volunteers. 
After giving informed consent, the 
volunteers filled out the International Physical 
Activity Questionnaire (IPAQ short form). The 
weekly physical activities of the participants were 
determined from IPAQ questionnaires and were 
categorised in low, moderate and high activity 
groups. The activity in MET.min.week-1 was also 
calculated numerically, according to the data processing 
rules given in the guide book.11 These are given in table-
2. The height, weight, heart rate and blood pressure of 
the volunteers were recorded. After collecting blood, it 
was centrifuged within 30 minutes and plasma was 
stored at -80◦C. All samples were thawed and brought to 
room temperature before analyses. The samples were 
analysed for plasma endostatin concentration, using 
QuantikinR ELISA kit bought from R&D systems. The 
samples were run in duplicates after dilution following 
the instructions of the manufacturer. A series of 
standards and controls were provided with each kit and 
these were used to generate calibration plots.  
Statistical analyses were carried out using 
SPSS 17. The normality of the data was tested using 
Kolmogorov- Smirinov and Shapiro-Wilk tests. 
Summary statistics were calculated. Independent sample 
t-tests were used to investigate difference between 
means for males and females. ANOVA was applied to 
check the difference between means of participants from 
different ethnic groups. Pearson correlations tests were 
used to investigate the correlations of endostatin with 
anthropometric and physical characteristics of the 
volunteers. Uni-variate and multivariate regressions 
analysis was done to investigate association of 
endostatin concentrations with other variables. 
Categorical data of physical activity was analysed 
using Chi-square tests. The data was analysed for 
different types of physical activity both in 
categorical (high, moderate and low physical 
activity) by Chi-square, and continuous forms 
(MET-min per week) by independent sample t-test. 
p-value less than 0.05 was accepted as significant. 
RESULTS 
Results were obtained for all 50 volunteers. All the 
data were normally distributed including MET 
minutes. Males were significantly older (p=0.021), 
taller (p<0.001) and heavier (p=0.006) than 
females (Table-2). No statistical differences were 
observed for other variables. Most of the 
participants had a moderate level of physical 
activity (Table-2). Chi square test showed no 
significant difference in physical activity levels 
between male and female volunteers (p=0.370). 
The mean value for plasma endostatin in all 
samples was 105±12 ng/ml (Mean±SD). The range 
of concentration observed in this data set was from 
81 to 132 ng/ml.  
The mean endostatin concentration for male 
was 107±13 ng/ml, while for females; it was 102±12 
ng/ml. When mean concentrations for both groups were 
compared, no significant difference was observed 
(p=0.21). The mean endostatin concentration for 
Europeans was 105±14 ng/ml, and for Asians was 
106±13 ng/ml, while for Middle Eastern was 106±7 
ng/ml (Table-3). No significant difference in endostatin 
concentration was found between ethnic groups 
(p=0.80). The difference in their physical characteristics 
are summarised in table-3.  
Correlation of endostatin with anthropometric 
and physical variables was checked in pooled data and 
also in data split by gender and ethnicity. In pooled data, 
there was no significant correlation. However, in male 
individuals, there was a significant negative correlation 
between heart rate and endostatin concentration 
(supplementary table 1). In data split by ethnicity and 
sex, no correlations were found for height, weight, SBP, 
DBP, BMI and MET minutes with endostatin 
concentration. Strong negative correlation was observed 
in Middle Eastern females for heart rate. South Asian 
males were positively correlated for age and DBP 
(supplementary table-2). In addition, the regression 
analyses were also inconclusive in providing any 
association between different anthropometric variables 
and plasma endostatin concentrations, as shown in table 
4. In uni-variate analysis heart rate and physical activity 
were significantly related with endostatin, however, no 
variable was related with endostatin in multi-variate 
analyses (Table-4). The overall value for R2 in multi-
variate analyses was 0.182 (18%).  
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Table-1: Evidence table of previous studies with different endostatin concentrations 
Reference 
Mean [ES] 
Plasma 
Mean [ES} Serum Mean Age years Assay Method Comments 
Standker et al 199712 10-10M   
Mass 
spectrometry 
Human plasma hemofiltrate was 
used for isolation of endostatin 
using mass spectrometry 
Healthy volunteers = 
9.9±9.7 ng/ml  
48.5±12.7 
Hebbar et al 200013  
Sclerosis patients 
63.2±20.2 ng/ml 
54.1±14.6 
Enzyme immune 
essay 
50 patients with different levels of 
established sclerosis were evaluated 
for plasma endostatin 
concentration. 
Feldman et al 200014  
Controls =14.1 ng/ml 
(1.0–19.3 ng/ml) 
Renal cancer patient 
=24.6 (15.1–54 
ng/ml) 
Patients=48 
Controls=age 
matched 
Competitive 
enzyme 
immunoassay 
Serum samples of at pre- 
nephrectomy stage of 15 renal 
cancer patients were analysed 
against fresh samples from 18 
healthy controls 
Zorick et al 20019  
Downs patients 
(38.6±20.1 ng/ml) 
Healthy controls 
(20.3±11.5 ng/ml) 
 ELISA 
Endostatin concentrations of Down 
syndrome patients were almost 
double to that of normal healthy 
volunteers. 
colorectal cancer 
patients (71.6±28.6 
ng/ml) 
 
60 years 
 
 Feldman et al 2001a15 
Healthy controls 
(43.2±15.1 ng/ml) 
 56 years 
Competitive 
enzyme 
immunoassay 
High endostatin concentrations 
were found in plasma of 30 
colorectal cancer patients. Elevated 
levels were associated with disease 
progression. 
Feldman et al 2001b16  
controls=25.8 ng/ml 
Sarcoma patients=43 
ng/ml  
Patients=44 yrs, 
Age matched for 
controls  
Competitive 
enzyme 
immunoassay 
Serum samples from 25 soft tissue 
cancer patients in pre-surgery states 
were analysed for endostatin and 
compared to controls. 
Gu et al 200417 20.3±3.2 ng/ml  
volunteers = 
33±13 
ELISA 
7 healthy volunteers performed 
high intensity exercise. Their 
baseline concentrations were 
checked before exercise. 
Teh et al 200418 
controls 
(34.97±3.76 ng/ml 
Patients 
(30.62±4.54 ng/ml) 
  ELISA 
Post-operative breast cancer 
patients had a higher endostatin 
concentrations in plasma compared 
to controls. 
Suhr et al 200710 87.3±5.7 ng/ml  27.8±5.4 
ELISA 
Western Blot 
In this study 12 male cyclists 
perform exercise with and without 
hypoxia and vibration, and their 
effect on angiogenesis. 
Smoker elderly 
(103.3±16 ng/ml) 
 
47.12 (39–62) 
 
Non-smoker 
elderly (116.3±15 
ng/ml) 
 51.55 (36–70) 
Young Non-
smoker (93.4±15 
ng/ml) 
 23.16 (18–34) 
Sponder et al 201119 
Diabetic (108.5±17 
ng/ml) 
 57.86 (42–70) 
ELISA 
Impact of exercise was checked on 
the plasma endostatin concentration 
in 17 elderly smokers, 20 non-
elderly smokers, 19 young healthy 
non-smokers and 14 type 2 
diabetics. Endostatin concentration 
was measured before and after 
exercise. 
Female athletes 
(129±21 ng/ml) 
 
26±5 
 
Female controls 
(89±15 ng/ml) 
 
23±4 
 
Male athletes 
(148±28 ng/ml) 
 
24±4 
 
Sponder et al 201320 
Male controls 
(93±15 ng/ml) 
 23±4 
ELISA 
Impact of bicycle exercise in 
athletes and sedentary males and 
females was checked. Baseline 
endostatin concentration was 
observed to be high in athletes than 
sedentary volunteers. Exercise 
increased the endostatin 
concentration in both groups. 
Makey et al 201321  111±5 ng/ml 24 ± 0.8 ELISA 
Low intensity exercise was 
performed in females belonging to 
African American (n=35, mean age 
26.1±1.21) and Caucasian (n=37 
mean age 22.1±0.84) ethnicities. 
No effect of exercise on plasma 
endostatin concentration was 
observed. 
A chronological arrangement of the different studies reporting the endostatin concentrations in healthy and diseased population is shown. Endostatin 
concentrations are outlined as mean±SD with ranges, where possible. Age of the participants and techniques used for analyses of endostatin are also 
given in separate columns. 
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Table-2: Characteristics of the participants 
 Total Female Male p-value 
Sample size (n) 50 16 34  
Age (Years) 26.7±7.80 23.1±4.4 28.5±8.5 0.021 
Height (m) 1.71±0.07 1.66±0.1 1.74±0.05 <0.001 
Weight (kg) 73.6±10.4 67.8±8.01 76.3±10.4 0.006 
BMI (kg/m2) 24.89±2.77 24.65±2.33 25.0±2.98 0.676 
Heart Rate (bpm) 75±5 77±6 73±5 0.090 
SBP (mm Hg) 123±9 118±12 125±7 0.059 
DBP (mm Hg) 74±8 73±8 74±8 0.378 
MET.min.week-1 2471±1627 2572±1536 2424±1689 0.768 
PA (High)% 38 50 32.4 
PA (Moderate)% 52 37.5 58.8 
PA (Low)% 10 12.5 8.8 
0.370 
p-value for the difference between males and females by independent sample t-test. Lower panel of table shows p-vale for Chi Square test for 
physical activity (PA). BMI; Body Mass index, SBP; Systolic blood pressure DBP; Diastolic blood pressure (values are presented as mean±SD), 
MET are the metabolic equivalent minutes of basal metabolic rate. PA; physical activity 
Table-3: Anthropometric and physical characteristics of volunteers from different regional groups 
  Europeans Asians Middle Eastern p- ANNOVA 
M 14 15 5  
F 11 - 5  Sample size (n) 
Total 25 15 10  
M 25±10.5 32±6.06 27.2±6.02 0.081 
F 21.2±1.6 - 27.6±4.5 0.009 Age (years) 
Total 23.3±8.1 32±6.06 27.4±5.04 0.004 
M 1.75±0.04 1.74±0.05 1.74±0.04 0.60 
F 1.67±0.1 - 1.62±0.1 0.24 Height (m) 
Total 1.72±0.1 1.73±0.05 1.68±0.08 0.08 
M 76.3±11.6 76.2±10.8 76.9±2.9 0.99 
F 68.9±8.3 - 65.6±7.8 0.46 Weight (kg) 
Total 73±10.7 76±10.8 71.2±9 0.15 
M 74±6 74±5 71±3 0.54 
F 76±6 - 78±5 0.60 HR 
Total 75±6 74±5 74±5 0.97 
M 127±5 122±9 127±2 0.11 
F 120±12 - 116±11 0.54 SBP 
Total 124±10 122±9 121±9 0.16 
M 77±9 72±7 78±5 0.18 
F 73±8 - 73±10 0.96 DBP 
Total 75±9 72±7 75±8 0.48 
M 2803±1704 2065±1695 2441±1747 0.50 
F 2850±1031 - 1958±2346 0.30 Met.min.week-1 
Total 2824±1420 2065±1695 2200±1967 0.48 
M 107±15 106±13 108±7 0.90 
F 101±14 - 103±7 0.70 Endostatin (ng/ml) 
Total 105±14 106±13 106±7 0.80 
Values are mean±SD. p-value for ANOVA 
Table-4: Regression analysis for endostatin with anthropometric and physical variables 
Endostatin Uni-variate Multi-variate 
 Beta (CI) p Beta (CI) p 
Age 0.13 (-18.1–46.7) 0.38 -0.05 (-50–39.0) 0.81 
Height 0.03 (-46–.355.4) 0.86 -0.55 (-6920–499.4) 0.75 
Weight -0.02 (-0.4–0.3) 0.87 0.78 (-6–7.8) 0.78 
Sex 0.18 (-2.8– -12.5) 0.21 0.10 (-9–14.1) 0.65 
BMI -0.06 (-1.6–1.1) 0.69 -0.65 (-24–17.7) 0.77 
SBP 0.16 (-0.2–0.6) 0.28 0.17 (0–0.8) 0.38 
DBP 0.17 (-0.2–0.7) 0.23 0.04 (-1–0.6) 0.81 
HR -0.27 (-1.3–0.009) 0.05 -0.29 (-1–0.1) 0.10 
MET_min.week-1 -0.21(-.004– .005) 0.15 0.06 (-.004–0.005) 0.84 
PA Level -0.23 (-10.2–0.9) 0.10 -0.27 (-16–5.5) 0.32 
Uni-variate and multi- variate regression analyses for all variables were carried out, as shown by Beta coefficient (Beta) with confidence intervals 
(CI) and significance (P). Multivariate analyses R2=0.182. 
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DISCUSSION 
In our healthy study population, the mean value for 
plasma endostatin in all samples was 105±12 ng/ml 
with range of 81–132 ng/ml. For males, it was 
107±13 ng/ml, while for females; it was 102±12 
ng/ml. The mean endostatin concentration for 
Europeans was 105±14 ng/ml, and for Asians was 
106±13 ng/ml, while for Middle Eastern was 106±7 
ng/ml. There was no significant gender or ethnicity 
related differences in endostatin concentration. 
Moreover, endostatin was not significantly related 
with any anthropometric and physical variable. These 
results are consistent with the results published by 
Sponder; mean concentration of 93.4±15.3 ng/ml19, 
and Suhr; 87.3±4.5 ng/ml10. The studies carried out 
by Sponder included 13 male healthy volunteers 
while the latter study had a sample size of 88. 
Another study published recently, reported mean 
endostatin concentration of 111±5 ng/ml, in 72 
healthy females.21 
However, these results are significantly 
different from the mean plasma endostatin 
concentration of 20.3 ng/ml reported by Gu17, 14.1 
ng/ml by Feldman14 and 43.2 ng/ml by Teh18, for 
healthy volunteers of different ages in their studies. 
These differences in concentrations could be 
attributed to the different techniques (ELISA, 
Western blot, Mass spectrometry etc) used for 
analyses. It should be noted from the studies listed in 
table-1, that more recent studies have reported 
comparatively high endostatin concentrations, which 
is pointing towards more sophistication and maturity 
of techniques with time. 
The sensitivity of the ELISA kits from 
different manufactures might be a factor. Different 
studies using the same ELISA kits (Accucyte, 
Cytimmune Sciences Inc., MD, USA) have reported 
a low endostatin concentration9,17, which could 
possibly be the reason for reporting low endostatin 
concentration. Moreover, the media used for analyses 
(plasma, serum, haemofiltrate) may have different 
sensitivity and specificity for the same techniques. 
Nonetheless, these differences are not completely 
clear because concentrations reported by the same 
author in different studies using the same techniques 
and media, show significant difference for healthy 
volunteers.14,15 One might speculate about the causes 
of these differences. Serum concentrations of 
endostatin have been reported to be affected by 
circadian rhythms22, age23,24 and physical activity17,23. 
It was not possible to address these factors in our 
study. 
The results in our study seems more reliable 
due to the larger sample size, good quality control 
indicators and the results lying within the range 
provided by the kit supplier. It is worth noting, that 
even this larger sample does not find volunteers with 
endostatin concentrations as low as those reported 
elsewhere.15,17 It is also unlikely that geographical 
variations could explain these differences as only 
minor differences were observed in European, 
Middle Eastern and South Asian populations in our 
study. The second aim of the study was to investigate 
the difference in concentration of endostatin between 
males and females. The mean plasma endostatin 
concentration appears higher in male than female 
volunteers. However, the difference is not 
statistically significant (p=0.21). These results are in 
agreement with the result from other studies, where 
the male shows more mean concentration than 
female.9,16 Though these studies have not mentioned 
any direct comparison between the two groups, the 
difference looks non-significant. In addition, another 
study which compared the concentration on gender 
basis also reported a slightly higher but non-
significant concentration in males.25  
The hypothesis tested in this study was that 
females might have lower concentrations of plasma 
endostatin. The basis of this expectation lies in the 
lower concentration of many biological molecules 
such as haemoglobin in females.26 Gu speculated that 
endostatin in circulation might be due to 
physiological collagen turnover.17 Based on this 
supposition, it can be assumed that more muscle mass 
in males may cause higher physiological collagen 
turnover which consequently might increase 
circulatory endostatin.  
Plasma endostatin concentrations in 
volunteers of different ages were also investigated. 
The volunteers had a broad range (19–60 years) of 
age. However, age of 96% of the participants were 40 
years and below. The oldest participant in the study 
was 60 years old male and his plasma concentration 
was 109 ng/ml, which is very near to the mean 
concentration. No significance correlation of plasma 
endostatin with age was found when the data from all 
volunteers was investigated. The data from the South 
Asian volunteers showed a positive correlation with 
age (p=0.049). Strong conclusion from this 
correlation cannot be drawn because; firstly, the p-
value is border line to significance, secondly sample 
size is small (n=15) and thirdly by including the male 
participants from Middle Eastern and European 
group, significance is lost (p=0.52), as shown in table 
supplementary table-2. However, significantly higher 
endostatin concentration in older participants than 
young adults have been reported previously.19,23 With 
advancing age the chances for angiogenic dependent 
diseases increases. It is possible that the circulatory 
endostatin concentration rises as an adaptive 
protective mechanism. 
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It was important to know that variations in physical 
and anthropometric characterises might affect the 
endostatin concentration in plasma. But the plasma 
endostatin concentration seemed uncorrelated with 
most of physical and anthropometric parameters such 
as height, weight, BMI and blood pressure. The 
author is unaware of any previous published data 
reporting these observations.  
Physical activity has been widely accepted 
to decrease the risk of cardiovascular related 
mortality and morbidity.27 The physical activities 
were assessed using the short form of International 
Physical Activity Questionnaire. They were 
categorised in low, moderate and high activity 
groups. The activity in MET.min.week-1 was also 
calculated numerically, according to the data 
processing rules given in the guide book.11 METs 
refer to multiples of resting metabolic rate during an 
activity. MET-minutes are the MET score of an 
activity during a specific time period. The analysis 
revealed no significant relationship between plasma 
endostatin concentration and reported physical 
activity (p=0.816).  
Higher concentrations of plasma 
endostatin were reported by Sponder in male and 
female athletes than in matched controls.20 This 
difference in results could be due to several 
factors. Perhaps habitual physical activity has 
different effects from shorter periods of intense 
athletic training. It was assumed before the study, 
that regular physical activity might have an effect 
on the basal endostatin concentration. As 
participants were mostly students of the University 
of Glasgow, their involvement in physical 
activities was expected to be more than population 
in general. To minimise this effect, all volunteers 
were asked to abstain from physical exercise for 24 
hours before the trial. However, under or over 
reporting of physical activities, unclear definitions 
of different intensities of activities, and the 
presence of the option “I don’t know” in the 
questionnaire, could be the possible reasons for the 
data of physical activity being unreliable. More 
sophisticated approaches such as using 
accelerometers and GPS devices, to monitor the 
physical activity behaviour of the participants prior 
to blood sampling, could have provided more 
accurate information. Due to large sample size, 
cost of the GPS devices was one of the barriers in 
implementations.  
The strengths of the study include; a wide 
sample size and inclusion of both male and female 
participants from different ethnic groups with wide 
range of age and other parameters including height, 
weight, BMI and heart rate. There were some 
limitations to the study such as more males (n=34) 
than females (n=16). This was not intentional and 
volunteers were recruited randomly. The results 
imply no difference on basis of gender and the 
imbalance between the number male and female 
participants may not have a profound influence on 
the results. However, the strength given to the results 
in setting the trends with a more evenly gender 
distribution, could not be rejected completely. 
Plasma samples were run in duplicate on 
ELISA kits to calculate mean values for each subject 
as compared to the classical triplicate pattern used in 
many studies. There are two reasons for this: firstly, 
the ELISA manufacturer instruction says the plasma 
samples to be run in duplicate and secondly time and 
financial restraints. Triplicate results might have 
produced more accurate mean result but the good 
quality control indicators (inter and intra assays CV% 
<10 & 5% respectively) show that handling technique 
of the plasma samples, controls and standards, 
including pipetting and different steps in the 
analyses, were carried out accurately. The differences 
in mean endostatin concentrations were small and 
triplicates would have minimal effects on the overall 
results. 
The experiment was not planned to 
investigate the difference in concentration in different 
regional groups. The regional groups were included 
only, when the initial statistics revealed no difference 
between the male and female participants and their 
demographic relationship with plasma endostatin 
concentration. This is also the reasons of the uneven 
distribution of participants in different ethnic groups. 
The results could be more reliable, had there been 
more participants in each group and study planned on 
more ethnic bases in the initial stage.  
This study gives the endostatin levels in 
normal healthy people and show no gender and 
ethnicity related differences in endostatin levels. It 
also shows that endostatin was not significantly 
related with any anthropometric and physical 
variable. Based on this study’s results, further 
research in to the effects of exercise on plasma 
endostatin concentration could be carried out 
without any specific gender or anthropometric 
requirements.  
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